We are joined by Antonis Kattamis at the EHA conference in Amsterdam to discuss his presentation on data from the DEEP-2 trial, a multicentre, randomised, non-inferiority trial comparing the efficacy of deferiprone versus deferasirox in paediatric patients affected by transfusion-dependent haemoglobinopathies.
1. What are the complications of lifelong red blood cell transfusions in transfusion-dependent thalassaemia (TDT)? (0:05)
2. How have recent therapeutic advances affected outcomes in TDT? (0:40)
3. Could you tell us a little about your recent study of TDT patients? (1:07)
4. What were the main factors affecting efficacy of iron chelation in this group of TDT patients? (1:50)
5. What can be done to further improve outcomes in this patient population? (2:38)
Antonis Kattamis has received study support, speaker fees and is a member of the advisory board for Novartis Oncology, and has received speaker fees from Apopharma.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Haematology
Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe […]
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!